[go: up one dir, main page]

BE2014C028I2 - - Google Patents

Info

Publication number
BE2014C028I2
BE2014C028I2 BE2014C028C BE2014C028C BE2014C028I2 BE 2014C028 I2 BE2014C028 I2 BE 2014C028I2 BE 2014C028 C BE2014C028 C BE 2014C028C BE 2014C028 C BE2014C028 C BE 2014C028C BE 2014C028 I2 BE2014C028 I2 BE 2014C028I2
Authority
BE
Belgium
Prior art keywords
treatment
tumors
bone
radium
bones
Prior art date
Application number
BE2014C028C
Other languages
French (fr)
Original Assignee
Bayer As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer As filed Critical Bayer As
Publication of BE2014C028I2 publication Critical patent/BE2014C028I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Materials For Medical Uses (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)

Abstract

Processes for the preparation, prepared solutions, and the use of radium-223 for the treatment of calcified tumors, bone tumors, treatment of bones, bone surfaces and soft tissues is described.
BE2014C028C 1999-01-04 2014-05-07 BE2014C028I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO990001A NO310544B1 (en) 1999-01-04 1999-01-04 Preparation and use of radium-223 for the preparation of preparations and kits for the treatment of calcified tissue for palliation, bone cancer therapy and / or bone surface treatment
PCT/NO1999/000392 WO2000040275A2 (en) 1999-01-04 1999-12-17 The preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning

Publications (1)

Publication Number Publication Date
BE2014C028I2 true BE2014C028I2 (en) 2019-03-05

Family

ID=19902803

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C028C BE2014C028I2 (en) 1999-01-04 2014-05-07

Country Status (24)

Country Link
US (2) US6635234B1 (en)
EP (1) EP1140212B1 (en)
JP (2) JP4649044B2 (en)
KR (1) KR100671387B1 (en)
CN (2) CN1767078B (en)
AT (1) ATE331534T1 (en)
AU (1) AU774991B2 (en)
BE (1) BE2014C028I2 (en)
BR (1) BR9916768A (en)
CA (1) CA2358498C (en)
CY (2) CY1105634T1 (en)
DE (1) DE69932183T2 (en)
DK (1) DK1140212T3 (en)
EA (1) EA003496B1 (en)
ES (1) ES2268888T3 (en)
IL (1) IL144135A0 (en)
LU (1) LU92425I2 (en)
MX (1) MXPA01006823A (en)
NO (2) NO310544B1 (en)
NZ (3) NZ513135A (en)
PT (1) PT1140212E (en)
TR (3) TR200102707T2 (en)
WO (1) WO2000040275A2 (en)
ZA (1) ZA200105431B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (en) * 1999-01-04 2001-07-23 Algeta As Preparation and use of radium-223 for the preparation of preparations and kits for the treatment of calcified tissue for palliation, bone cancer therapy and / or bone surface treatment
NO314537B1 (en) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Receptor binding conjugates
NO313180B1 (en) 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Visiting alpha particles emitting radiopharmaceuticals
AUPQ923100A0 (en) * 2000-08-07 2000-08-31 Peplin Research Pty Ltd Treatment of prostate cancer
WO2003061566A2 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
GB0213261D0 (en) * 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
JP4998916B2 (en) 2003-04-30 2012-08-15 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド Method and apparatus for radiation therapy
BRPI0507824A (en) * 2004-02-20 2007-07-10 Algeta As hydroxyapatite, process for the preparation of a radionuclide-labeled hydroxyapatite particulate, pharmaceutical composition, use of hydroxyapatite and an alpha-emitting radionuclide or a beta-emitting radionuclide, device, and, method of radiochemical treatment of a human or human individual non-human animal needing the same
DE102004022200B4 (en) * 2004-05-05 2006-07-20 Actinium Pharmaceuticals, Inc. Radium target and process for its preparation
US7914766B1 (en) * 2004-06-03 2011-03-29 Ut-Battelle Llc Inorganic resins for clinical use of 213Bi generators
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
HUE037796T2 (en) * 2005-07-26 2018-09-28 Aplha Tau Medical Ltd A radioactive surface source and a method for producing the same
US8709380B1 (en) * 2006-02-07 2014-04-29 Sirius Medicine, Llc Targeting agents for enhancing radiation therapy
DE102006008023B4 (en) * 2006-02-21 2008-05-29 Actinium Pharmaceuticals, Inc. Method of cleaning 225Ac from irradiated 226Ra targets
CA2950532C (en) 2006-09-08 2018-10-23 Actinium Pharmaceuticals, Inc. Method for the purification of radium from different sources
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201007353D0 (en) 2010-04-30 2010-06-16 Algeta Asa Method
GB201007354D0 (en) * 2010-04-30 2010-06-16 Algeta Asa Method
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
CA2895356A1 (en) 2012-12-19 2014-06-26 Bayer Pharma Aktiengesellschaft Combination comprising radium-223 for the treatment of cancer
GB201314718D0 (en) * 2013-08-16 2013-10-02 Algeta As Quantification method
CN105934256B (en) 2013-12-03 2019-12-27 拜耳制药股份公司 PI3K inhibitor combination
EP3077003A1 (en) 2013-12-03 2016-10-12 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
MX2016007285A (en) 2013-12-17 2016-08-04 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS.
WO2016083739A1 (en) 2014-11-26 2016-06-02 Rhodia Operations Composition comprising lanthanum and actinium-227
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
CZ2016821A3 (en) * 2016-12-22 2018-07-04 České vysoké učení technické v Praze A combination for radionuclide therapy for the use as a medicine
UY37616A (en) 2017-02-24 2018-09-28 Bayer Ag COMBINATION OF QUINASA ATR INHIBITORS WITH RADIO SALT-223
KR102560243B1 (en) 2017-05-11 2023-07-27 알파 타우 메디컬 리미티드 Polymer coatings for brachytherapy devices
AU2019247818B2 (en) 2018-04-02 2021-10-14 Alpha Tau Medical Ltd. Controlled release of radionuclides
EP3563875A1 (en) * 2018-05-04 2019-11-06 Ceské vysoké ucení technické v Praze Radium for radionuclide therapy, in combination with calcium metabolism affecting treatment
LU100900B1 (en) * 2018-08-10 2020-02-17 Thomas Melchior Homann COMPOUNDS FOR MODULATING A-KETOGLUTARIC ACID (2KG) -DEPENDENT OXYGENASES
FR3086186B1 (en) * 2018-09-26 2022-01-28 Orano Med METHOD FOR THE PRODUCTION OF LEAD-212 FROM AN AQUEOUS SOLUTION COMPRISING THORIUM-228 AND ITS DESCENDANTS
FR3088769B1 (en) * 2018-11-15 2020-12-25 Orano Med PROCESS FOR PREPARING AT LEAST ONE GENERATOR WITH HIGH RADIUM-228 CONTENT
US20220152228A1 (en) * 2019-03-01 2022-05-19 Washington University Compositions and methods for radiotherapy using chelated radiotherapeutic agents and non-target tissue blockade
RU2752845C1 (en) * 2020-05-13 2021-08-11 Акционерное Общество "Наука И Инновации" Method for obtaining high-purity radium-223
WO2022130195A1 (en) * 2020-12-16 2022-06-23 Alpha Tau Medical Ltd. Diffusing alpha-emitters radiation therapy with enhanced beta treatment
CN113066598B (en) * 2021-03-25 2023-08-08 中国科学院近代物理研究所 Irradiation from high-energy proton beam 232 Separation and purification in spallation reaction caused by Th target 223 Method for Ra
US12070621B2 (en) 2021-06-10 2024-08-27 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for pancreatic cancer
US12076583B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for melanoma
US12076581B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for glioblastoma
US12042668B2 (en) 2021-06-10 2024-07-23 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for squamous cell carcinoma
US12070620B2 (en) 2021-06-10 2024-08-27 Alpha Tau Medical Ltd. Activity levels for diffusing alpha-emitter radiation therapy
US11964168B2 (en) 2021-06-10 2024-04-23 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for prostate cancer
US12076582B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for colorectal cancer
US12064643B2 (en) 2021-06-10 2024-08-20 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for breast cancer
JP2025507615A (en) 2022-02-21 2025-03-21 バイエル・ヘルスケア・エルエルシー Systems, methods and devices for the delivery of therapeutic or diagnostic agents - Patents.com
US20250195918A1 (en) 2022-02-21 2025-06-19 Bayer Healthcare Llc System, Method and Device for Delivery of a Therapeutic or Diagnostic Agent
CN115869658B (en) * 2022-12-29 2025-01-28 中国核动力研究设计院 Separation system for preparing Ra-223, separation method, application and preparation method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH668489A5 (en) * 1982-01-22 1988-12-30 Vnii Mineralnogo Syrya RADIOMETRIC METHOD FOR DETERMINING THE CONCENTRATION OF NATURAL RADIUM ISOTOPES AND DEVICE FOR IMPLEMENTING THE METHOD.
JPH04501265A (en) * 1988-10-14 1992-03-05 マリンクロッド・インコーポレイテッド Radiolabeled particulate composition
US4970062A (en) * 1989-05-30 1990-11-13 The United States Of America As Represented By The United States Department Of Energy Colloid labelled with radionuclide and method
CA2123588A1 (en) * 1991-11-14 1993-05-27 Frederick C. Leung Method for diagnosing and treating cancer
EP0700304A4 (en) * 1993-05-17 1999-01-07 Immunomedics Inc Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
US5809394A (en) * 1996-12-13 1998-09-15 Battelle Memorial Institute Methods of separating short half-life radionuclides from a mixture of radionuclides
US6117413A (en) * 1997-11-12 2000-09-12 Battelle Memorial Institute Radionuclide-binding compound, a radionuclide delivery system, a method of making a radium complexing compound, a method of extracting a radionuclide, and a method of delivering a radionuclide
NO310544B1 (en) * 1999-01-04 2001-07-23 Algeta As Preparation and use of radium-223 for the preparation of preparations and kits for the treatment of calcified tissue for palliation, bone cancer therapy and / or bone surface treatment
NO314537B1 (en) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Receptor binding conjugates
NO312708B1 (en) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioactive liposomes for therapy
NO313180B1 (en) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Visiting alpha particles emitting radiopharmaceuticals
GB0213261D0 (en) * 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
US20060228297A1 (en) * 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy

Also Published As

Publication number Publication date
TR200102707T2 (en) 2002-03-21
JP2002534399A (en) 2002-10-15
ES2268888T3 (en) 2007-03-16
CY2014020I2 (en) 2015-12-09
KR20010092772A (en) 2001-10-26
CN1194764C (en) 2005-03-30
NO310544B1 (en) 2001-07-23
DE69932183T2 (en) 2007-05-16
MXPA01006823A (en) 2003-07-14
IL144135A0 (en) 2002-05-23
NO990001D0 (en) 1999-01-04
CA2358498C (en) 2008-09-16
DE69932183D1 (en) 2006-08-10
DK1140212T3 (en) 2006-10-09
PT1140212E (en) 2006-11-30
CY1105634T1 (en) 2010-12-22
CA2358498A1 (en) 2000-07-13
EP1140212B1 (en) 2006-06-28
US20030206857A1 (en) 2003-11-06
CN1767078B (en) 2012-01-11
EA003496B1 (en) 2003-06-26
NZ545023A (en) 2007-08-31
JP5433490B2 (en) 2014-03-05
WO2000040275A3 (en) 2001-06-21
EP1140212A2 (en) 2001-10-10
NO990001L (en) 2000-07-05
HK1090750A1 (en) 2006-12-29
NZ534618A (en) 2006-03-31
NO2014010I1 (en) 2014-06-02
NZ513135A (en) 2004-09-24
ATE331534T1 (en) 2006-07-15
CY2014020I1 (en) 2015-12-09
CN1335779A (en) 2002-02-13
EA200100642A1 (en) 2002-02-28
TR200201442T2 (en) 2002-08-21
US6635234B1 (en) 2003-10-21
NO2014010I2 (en) 2014-05-09
TR200201440T2 (en) 2002-08-21
ZA200105431B (en) 2002-07-02
CN1767078A (en) 2006-05-03
JP4649044B2 (en) 2011-03-09
AU1700400A (en) 2000-07-24
JP2010168397A (en) 2010-08-05
BR9916768A (en) 2001-12-04
LU92425I2 (en) 2014-06-10
AU774991B2 (en) 2004-07-15
KR100671387B1 (en) 2007-01-19
WO2000040275A2 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
NO2014010I2 (en)
MY155913A (en) Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transpants
MXPA03006771A (en) Modified antibodies and methods of use.
WO2002041837A3 (en) Treatment of mucositis
FR2721198B1 (en) Flexible implantable prosthesis, used in surgery for volume increase or soft tissue reconstruction, in particular breast prosthesis.
AU5845099A (en) Use of (pex) in the treatment of metabolic bone diseases
MY164077A (en) Compositions and uses of et743 for treating cancer
EP1162956B8 (en) Compositions and methods for improving integrity of compromised body passageways and cavities
AU1233701A (en) Methods and compositions for treating atheroma, tumors and other neoplastic tissue
AU2001234831A1 (en) Magnetoliposome composition for targeted treatment of biological tissue and associated methods
AU1907001A (en) Instrument (osteotome) for forming holes in bone tissue, preferably in jaw-bone tissue
UA32302A (en) Method for preventing postoperative deformities of soft tissues
MD1268B2 (en) Method for surgical treatment of meta-physar fracture of children should bone distal part
AU5760596A (en) Component b as cicatrizant
UA32173A (en) Methods for treating underdeveloped middle area of facial skeleton
UA33331A (en) Method for prophylactics of purulo-septic complications at after-operation period
UA32315A (en) Technique for skin suturing
UA32153A (en) Technique for generating graft for pull-through proctectomy
IT1317076B1 (en) Anti-inflammatory, non-steroid preparation useful for treating osteoarticular afflictions and soft tissue
UA32109A (en) Method for pharyngoesophagostomaplasty
UA40998A (en) Method for shin amputation
AU2002217680A1 (en) Surface modification of implants for healing in bone and soft tissue
SI1196159T1 (en) Use of tosylchloramide(s) for treating diseases of the skin, mucous membranes, organs and tissues
UA32174A (en) Method for surgical treatment of supraorbital hemiangioma
AU2001240529A1 (en) Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof